Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 2
1981 1
1982 2
1983 8
1984 12
1985 12
1986 8
1987 13
1988 9
1989 11
1990 12
1991 9
1992 15
1993 12
1994 5
1995 9
1996 7
1997 8
1998 13
1999 18
2000 8
2001 8
2002 5
2003 16
2004 14
2005 11
2006 7
2007 6
2008 11
2009 7
2010 9
2011 12
2012 11
2013 11
2014 11
2015 12
2016 10
2017 8
2018 8
2019 12
2020 12
2021 14
2022 6
2023 3
2024 3
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

390 results

Results by year

Filters applied: . Clear all
Page 1
A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease.
Schuppan D, Mäki M, Lundin KEA, Isola J, Friesing-Sosnik T, Taavela J, Popp A, Koskenpato J, Langhorst J, Hovde Ø, Lähdeaho ML, Fusco S, Schumann M, Török HP, Kupcinskas J, Zopf Y, Lohse AW, Scheinin M, Kull K, Biedermann L, Byrnes V, Stallmach A, Jahnsen J, Zeitz J, Mohrbacher R, Greinwald R; CEC-3 Trial Group. Schuppan D, et al. Among authors: scheinin m. N Engl J Med. 2021 Jul 1;385(1):35-45. doi: 10.1056/NEJMoa2032441. N Engl J Med. 2021. PMID: 34192430 Free article. Clinical Trial.
Transcriptomic analysis of intestine following administration of a transglutaminase 2 inhibitor to prevent gluten-induced intestinal damage in celiac disease.
Dotsenko V, Tewes B, Hils M, Pasternack R, Isola J, Taavela J, Popp A, Sarin J, Huhtala H, Hiltunen P, Zimmermann T, Mohrbacher R, Greinwald R, Lundin KEA, Schuppan D, Mäki M, Viiri K; CEC-3 Investigators. Dotsenko V, et al. Nat Immunol. 2024 Jul;25(7):1218-1230. doi: 10.1038/s41590-024-01867-0. Epub 2024 Jun 24. Nat Immunol. 2024. PMID: 38914866 Free PMC article. Clinical Trial.
Probiotic With or Without Fiber Controls Body Fat Mass, Associated With Serum Zonulin, in Overweight and Obese Adults-Randomized Controlled Trial.
Stenman LK, Lehtinen MJ, Meland N, Christensen JE, Yeung N, Saarinen MT, Courtney M, Burcelin R, Lähdeaho ML, Linros J, Apter D, Scheinin M, Kloster Smerud H, Rissanen A, Lahtinen S. Stenman LK, et al. Among authors: scheinin m. EBioMedicine. 2016 Nov;13:190-200. doi: 10.1016/j.ebiom.2016.10.036. Epub 2016 Oct 26. EBioMedicine. 2016. PMID: 27810310 Free PMC article. Clinical Trial.
Response to Letter to the Editor.
Cajander P, Omari T, Scheinin H, Scheinin M, Savilampi J. Cajander P, et al. Among authors: scheinin m. Neurogastroenterol Motil. 2023 Aug;35(8):e14616. doi: 10.1111/nmo.14616. Epub 2023 May 29. Neurogastroenterol Motil. 2023. PMID: 37246925
Developing Topics.
Zetterberg H, Rinne JO, Sandberg A, Lovró Z, Scheinin M, Pierrou S, Harting K. Zetterberg H, et al. Among authors: scheinin m. Alzheimers Dement. 2024 Dec;20 Suppl 8(Suppl 8):e095440. doi: 10.1002/alz.095440. Alzheimers Dement. 2024. PMID: 39783352 Free PMC article. Clinical Trial.
Safety, tolerability and immunogenicity of PRV-101, a multivalent vaccine targeting coxsackie B viruses (CVBs) associated with type 1 diabetes: a double-blind randomised placebo-controlled Phase I trial.
Hyöty H, Kääriäinen S, Laiho JE, Comer GM, Tian W, Härkönen T, Lehtonen JP, Oikarinen S, Puustinen L, Snyder M, León F, Scheinin M, Knip M, Sanjuan M. Hyöty H, et al. Among authors: scheinin m. Diabetologia. 2024 May;67(5):811-821. doi: 10.1007/s00125-024-06092-w. Epub 2024 Feb 19. Diabetologia. 2024. PMID: 38369573 Free PMC article. Clinical Trial.
Experimental evolution gone wild.
Scheinin M, Riebesell U, Rynearson TA, Lohbeck KT, Collins S. Scheinin M, et al. J R Soc Interface. 2015 May 6;12(106):20150056. doi: 10.1098/rsif.2015.0056. J R Soc Interface. 2015. PMID: 25833241 Free PMC article.
Molecular pharmacology of alpha 2-adrenoceptor subtypes.
Aantaa R, Marjamäki A, Scheinin M. Aantaa R, et al. Among authors: scheinin m. Ann Med. 1995 Aug;27(4):439-49. doi: 10.3109/07853899709002452. Ann Med. 1995. PMID: 8519505 Free article. Review.
α2-adrenoceptor regulation of blood glucose homeostasis.
Fagerholm V, Haaparanta M, Scheinin M. Fagerholm V, et al. Among authors: scheinin m. Basic Clin Pharmacol Toxicol. 2011 Jun;108(6):365-70. doi: 10.1111/j.1742-7843.2011.00699.x. Epub 2011 Apr 11. Basic Clin Pharmacol Toxicol. 2011. PMID: 21418144 Free article. Review.
390 results